469 Combining a safe PI3Kd inhibitor with chemotherapy and anti-PD1 in immunotherapy-refractory NSCLC: a proof-of-concept study to allow clinical trial design

• Silvia Novello,
• Chiara Riganti,
• Luisella Righi,
• Fabrizio Tabbò,
• Lars van der Veen,
• Michael Lahn,
• Giusy Di Conza,
• Giorgio Scagliotti,
• Laurence Neff

Affiliations

Silvia Novello

University of Turin, AOU San Luigi Gonzaga, Orbassano, Turin, Italy

Chiara Riganti

1University of Torino, Torino, Piemonte, Italy

Luisella Righi

14 Pathology Unit, Department of Oncology, University of Turin, Turin, Italy

Fabrizio Tabbò

2Thoracic oncology unit, San Luigi Hospital, University of Turin, Torino, Piemonte, Italy

Lars van der Veen

4iOnctura SA, Geneva, Vaud, Switzerland

Michael Lahn

4iOnctura SA, Geneva, Vaud, Switzerland

Giusy Di Conza

4iOnctura SA, Geneva, Vaud, Switzerland

Giorgio Scagliotti

2Thoracic oncology unit, San Luigi Hospital, University of Turin, Torino, Piemonte, Italy

Laurence Neff

4iOnctura SA, Geneva, Vaud, Switzerland